CDK4 and diffuse intrinsic pontine glioma: DeWire et al. also conducted a phase I/II trial to identify the safety, feasibility, and early efficacy of ribociclib (CDK4/6-inhibitor) in 9 newly diagnosed DIPG patients [28].